Carey OConnor Kolaja - Jun 15, 2023 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
Director
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
Jun 15, 2023
Transactions value $
-$25,300
Form type
4
Date filed
6/20/2023, 04:25 PM
Previous filing
May 5, 2023
Next filing
May 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Options Exercise $45.3K +2.5K +15.1% $18.12 19.1K Jun 15, 2023 Direct
transaction RVNC Common Stock Sale -$70.6K -2.5K -13.12% $28.24 16.6K Jun 15, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVNC Stock Option (Right to buy) Options Exercise $0 -2.5K -23.24% $0.00 8.26K Jun 15, 2023 Common Stock 2.5K $18.12 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated March 16, 2023 by Ms. Kolaja.
F2 The shares subject to the stock option vested on May 4, 2023.